×
Illumina Inventory 2010-2024 | ILMN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Illumina inventory for the quarter ending December 31, 2024 was
$0.547B
, a
6.81% decline
year-over-year.
Illumina inventory for 2024 was
$0.547B
, a
6.81% decline
from 2023.
Illumina inventory for 2023 was
$0.587B
, a
3.35% increase
from 2022.
Illumina inventory for 2022 was
$0.568B
, a
31.79% increase
from 2021.
View More
Illumina Inventory 2010-2024 | ILMN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Illumina inventory for 2024 was
$0.547B
, a
6.81% decline
from 2023.
Illumina inventory for 2023 was
$0.587B
, a
3.35% increase
from 2022.
Illumina inventory for 2022 was
$0.568B
, a
31.79% increase
from 2021.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$231.2B
Amgen (AMGN)
$160B
Gilead Sciences (GILD)
$137.1B
Vertex Pharmaceuticals (VRTX)
$123.3B
Bristol Myers Squibb (BMY)
$113.2B
CSL (CSLLY)
$80.1B
GSK (GSK)
$76.6B
Regeneron Pharmaceuticals (REGN)
$76.1B
Argenex SE (ARGX)
$39.3B
Alnylam Pharmaceuticals (ALNY)
$32.5B
BioNTech SE (BNTX)
$28.3B
BeiGene (ONC)
$23.9B
Biogen (BIIB)
$20.1B
Insmed (INSM)
$15B
Genmab (GMAB)
$14.9B
Genmab (GNMSF)
$14.7B
Incyte (INCY)
$13.8B
Intra-Cellular Therapies (ITCI)
$13.7B
BioMarin Pharmaceutical (BMRN)
$13.1B
Moderna (MRNA)
$13B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
Sarepta Therapeutics (SRPT)
$10.4B
Bio-Techne Corp (TECH)
$10.4B
Vaxcyte (PCVX)
$10.3B
Exelixis (EXEL)
$9.8B
Ascendis Pharma (ASND)
$9.4B
Exact Sciences (EXAS)
$9.2B
Repligen (RGEN)
$9.1B
Bio-Rad Laboratories (BIO.B)
$8.7B
QIAGEN (QGEN)
$8.6B